- Home
- FATE
as 04-25-2025 4:00pm EST
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.
| Founded: | 2007 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 108.2M | IPO Year: | 2013 |
| Target Price: | $5.43 | AVG Volume (30 days): | 2.5M |
| Analyst Decision: | Hold | Number of Analysts: | 8 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.64 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.66 - $5.92 | Next Earning Date: | 05-08-2025 |
| Revenue: | $13,631,000 | Revenue Growth: | -78.55% |
| Revenue Growth (this year): | -66.69% | Revenue Growth (next year): | -22.90% |
Latest Fate Therapeutics Inc. News
FATE Breaking Stock News: Dive into FATE Ticker-Specific Updates for Smart Investing
Zacks
11 days ago
Fate Therapeutics' Lupus Candidate FT819 Gets FDA RMAT Tag
MT Newswires
12 days ago
Fate Therapeutics Receives FDA's Regenerative Medicine Advanced Therapy Designation for Lupus Cell Therapy; Shares Fall
GlobeNewswire
12 days ago
Fate Therapeutics Receives Regenerative Medicine Advanced Therapy (RMAT) Designation from FDA for FT819 to Treat Moderate to Severe Systemic Lupus Erythematosus (SLE)
Zacks
22 days ago
Fate Therapeutics (FATE) Down 34.6% Since Last Earnings Report: Can It Rebound?
GlobeNewswire
24 days ago
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Simply Wall St.
2 months ago
Fate Therapeutics, Inc. (NASDAQ:FATE) Just Reported, And Analysts Assigned A US$6.00 Price Target
Zacks
2 months ago
FATE Q4 Earnings Beat, Autoimmunity, Oncology Programs in Focus
Zacks
2 months ago
Fate Therapeutics (FATE) Reports Q4 Loss, Tops Revenue Estimates
Compare FATE vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "FATE Fate Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.